| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/05/2001 | US6242610 Reacting phenylmethyl 5-(6,8-diaza-6-(2-x-acetyl)-7-oxo-3-thiabicyclo(3.3.0)oct-2-yl)pentanoate with hiv protease to reduce the activity of the protease |
| 06/05/2001 | US6242606 Reacting a a,a-dimethylphenylacetic acid amide with a w-halo compound produces w'-halo-a-keto-a,a-dimethylphenylacetic acid amide and reacting it with a piperidine compound; 2-(4-(4-chloro-butyryl)-phenyl)-2-methy-propionic acid |
| 06/05/2001 | US6242601 Heterocyclic sulfamides |
| 06/05/2001 | US6242590 Antisense modulation of zinc finger protein-217 expression |
| 06/05/2001 | US6242575 Antibodies for detecting p27 protein |
| 06/05/2001 | US6242497 Use of 6,7-substituted 2-aminotetralines suitable for preparing a pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 06/05/2001 | US6242492 N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid in iron chelating therapy |
| 06/05/2001 | US6242491 Administering creatine phosphate for wrinkle, aging, and solar radiation resistance and as free radical scavenger |
| 06/05/2001 | US6242482 Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
| 06/05/2001 | US6242479 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/05/2001 | US6242477 Pharmaceutical compositions containing pyrylium compounds, pyrylium salts and process for manufacturing a medicament containing the aforesaid compounds |
| 06/05/2001 | US6242476 Leukotriene A4 hydrolase inhibitors |
| 06/05/2001 | US6242468 Carbamate and urea compositions and neurotrophic uses |
| 06/05/2001 | US6242467 Compounds |
| 06/05/2001 | US6242462 Novel decahydroisoquinoline derivatives which are selective glur5 receptor antagonists. |
| 06/05/2001 | US6242461 Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
| 06/05/2001 | US6242455 Inhibiting a matrix metalloprotease associated disease |
| 06/05/2001 | US6242449 Treating prostatic hypertrophy, urination disorders associated with prostatic hypertrophy, male pattern alopecia, or acne |
| 06/05/2001 | US6242438 3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 06/05/2001 | US6242435 Compositions and methods of treating abnormal cell proliferation |
| 06/05/2001 | US6242415 Mediation of cytokines by melanin |
| 06/05/2001 | US6242255 Protein which induces interferon-gamma production by immunocompetent cell |
| 06/05/2001 | US6242249 Nucleotide sequences of trigger factor chaperones from staphylococcus; diagnosis; probes; primers; vaccines; bactericides; bacteriostats; antibodies; drug screening |
| 06/05/2001 | US6242238 Nucleotide sequence which codes for heparinase; drug screening for antimetastasis/antinflammatory agents, angiogenesis inhibitors, wound healing agents; treatment for angioplasty-induced restenosis and atherosclerosis |
| 06/05/2001 | US6242218 Dna construct for altering gene expression of endogenous granulocyte-colony stimulating factor in mammalian cell; gene therapy; culture production |
| 06/05/2001 | US6242003 Organic compounds |
| 06/05/2001 | US6241993 Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin |
| 06/05/2001 | US6241981 Composition and method for repairing neurological tissue |
| 06/05/2001 | US6241710 Hypodermic needle with weeping tip and method of use |
| 06/05/2001 | CA2216163C Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 06/03/2001 | CA2327385A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/03/2001 | CA2327256A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/01/2001 | CA2327140A1 Novel protein conjugates and process for the preparation thereof |
| 05/31/2001 | WO2001038878A2 Pin1 as a marker for abnormal cell growth |
| 05/31/2001 | WO2001038566A2 Screening method for candidate drugs |
| 05/31/2001 | WO2001038564A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| 05/31/2001 | WO2001038532A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/31/2001 | WO2001038529A1 Novel polypeptide, novel dna, novel anitbody and novel transgenic animal |
| 05/31/2001 | WO2001038503A2 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | WO2001038486A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001038396A1 Collagen |
| 05/31/2001 | WO2001038393A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 05/31/2001 | WO2001038344A2 Modulation of signal transduction |
| 05/31/2001 | WO2001038339A1 Antimitotic compounds |
| 05/31/2001 | WO2001038332A1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 05/31/2001 | WO2001038326A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038324A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/31/2001 | WO2001038323A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | WO2001038322A1 Inhibitors of histone deacetylase |
| 05/31/2001 | WO2001038318A1 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/31/2001 | WO2001038315A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038311A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | WO2001038305A2 Novel il-8 receptor antagonists |
| 05/31/2001 | WO2001037865A1 Compositions and methods for treatment of allergic disorders |
| 05/31/2001 | WO2001037861A1 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| 05/31/2001 | WO2001037857A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001037852A2 Methods of inhibiting atrophy or promoting hypertrophy |
| 05/31/2001 | WO2001037848A1 Mixture of pomegranate seed oil and juice products |
| 05/31/2001 | WO2001037840A1 Methods for treating mild cognitive impairment |
| 05/31/2001 | WO2001037838A1 Ophthalmic aqueous preparation |
| 05/31/2001 | WO2001037835A1 Novel compounds |
| 05/31/2001 | WO2001037833A1 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
| 05/31/2001 | WO2001037827A1 Therapeutic intervention to mimic the effect of caloric restriction |
| 05/31/2001 | WO2001037826A1 Npyy5 antagonists |
| 05/31/2001 | WO2001037824A1 Use of 5ht3 agonists for relaxing the fundus |
| 05/31/2001 | WO2001037820A2 Ionizable indolinone derivatives and their use as ptk ligands |
| 05/31/2001 | WO2001037819A2 Use of indirubine derivatives for making medicines |
| 05/31/2001 | WO2001037818A2 Medicament and combination of compatible medicaments |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037807A1 Modular targeted liposomal delivery system |
| 05/31/2001 | WO2001037785A2 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | WO2001037780A2 Urotensin-ii analogs |
| 05/31/2001 | WO2001037667A1 Combination of n-phenyl-n'-benzoyl urea derivative and nectin compounds for parasite control |
| 05/31/2001 | WO2001009103A3 Imidazole antiproliferative agents |
| 05/31/2001 | WO2001002598A3 Screening for compounds modulating mitochondrial proton leak |
| 05/31/2001 | WO2000075172A3 Factor viia inhibitors |
| 05/31/2001 | WO2000073307A3 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 05/31/2001 | WO2000069472A3 Enzyme-activated anti-tumor prodrug compounds |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000057864A3 Cyclic glycerophosphates and analogs thereof |
| 05/31/2001 | WO2000042071A3 Compounds and methods to inhibit or augment an inflammatory response |
| 05/31/2001 | WO2000010507A3 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 05/31/2001 | WO2000006712A3 Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | US20010002419 Homogeneous preparation of protein, e.g. leptin, modified at the N-terminal only by an anhydride, e.g. succinic anhydride, ethylenediaminetetraacetic dianhydride; improved solubility; no inflammation at injection sites |
| 05/31/2001 | US20010002407 Isolated cherry extract containing anthocyanins, bioflavonoids and phenolics as antiinflammatory and antiarthritic agents; food additives; tablets; enzyme inhibitors |
| 05/31/2001 | US20010002401 Establishing the status of the mammal as presently or prospectively being in early stages of degeneration of articular cartilage or subchondral bone in one or more joinsts, administering a xanthine chondroprotective compound |
| 05/31/2001 | US20010002398 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 05/31/2001 | US20010002396 Comprising a vitamin D analog and a retinoid, vitamin D analog is capable of binding a vitamin D receptor and the retinoid consisting of a compound capable of binding a retinoic acid receptor; treats abnormal cell proliferation |
| 05/31/2001 | DE10058310A1 2-(3,5-Bistrifluormethylphenyl)-N-methyl-N-(6- morpholin-4-yl-4-o-tolylpyridin -3-yl ) isobutyramid 2- (3,5-Bis-trifluoromethyl) -N-methyl-N- (6-morpholin-4-yl-4-o-tolylpyridine -3-yl) -isobutyramide |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2704975A1 Therapeutic intervention to mimic the effect of caloric restriction |
| 05/31/2001 | CA2395564A1 Novel compounds |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2392495A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |